Vorapaxar's benefits exceed risks in select patients only

By  

Reactions Weekly, Vol. 1, Iss. 1396, 2012-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Vorapaxar: a novel protease-activated receptor-1 inhibitor

By Gurbel Paul A   Jeong Young-Hoon   Tantry Udaya S  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 10, 2011-10 ,pp. : 1445-1453

Informa Healthcare

Access to resources Recommend Favorite

Thrombin Receptor Antagonists for the Treatment of Atherothrombosis: Therapeutic Potential of Vorapaxar and E-5555

By Leonardi Sergio   Tricoci Pierluigi   Becker Richard C.  

Drugs, Vol. 70, Iss. 14, 2010-10 ,pp. : 1771-1783

Adis International

Access to resources Recommend Favorite

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers

By  

Clinical Pharmacology In Drug Development, Vol. 7, Iss. 2, 2018-02 ,pp. : 143-150

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR‐1 Antagonist, in Healthy Adult Subjects

By  

Clinical Pharmacology In Drug Development, Vol. 2, Iss. 4, 2013-10 ,pp. : 310-315

John Wiley & Sons Inc

Access to resources Recommend Favorite